Megan Trieu1, Steven G DuBois1, Elizabeth Pon1, Lorenzo Nardo2, Randall A Hawkins2, Araz Marachelian3, Clare J Twist4, Julie R Park5, Katherine K Matthay1. 1. Department of Pediatrics, UCSF School of Medicine and UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, California. 2. Department of Radiology, UCSF School of Medicine and UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, California. 3. Department of Pediatrics, Keck School of Medicine, University of Southern California and Children's Hospital Los Angeles, Los Angeles, California. 4. Department of Pediatrics, Lucile Packard Children's Hospital, Palo Alto, California. 5. Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington.
Abstract
BACKGROUND: (131) I-metaiodobenzylguanidine ((131) I-MIBG) is a targeted radiopharmaceutical for patients with neuroblastoma. Despite its tumor-specific uptake, the treatment with (131) I-MIBG results in whole-body radiation exposure. Our aim was to correlate whole-body radiation dose (WBD) from (131) I-MIBG with tumor response, toxicities, and other clinical factors. METHODS: This retrospective cohort analysis included 213 patients with high-risk neuroblastoma treated with (131) I-MIBG at UCSF Benioff Children's Hospital between 1996 and 2015. WBD was determined from radiation exposure rate measurements. The relationship between WBD ordered tertiles and variables were analyzed using Cochran-Mantel-Haenszel test of trend, Kruskal-Wallis test, and one-way analysis of variance. Correlation between WBD and continuous variables was analyzed using Pearson correlation and Spearman rank correlation. RESULTS: WBD correlated with (131) I-MIBG administered activity, particularly with (131) I-MIBG per kilogram (P < 0.001). Overall response rate did not differ significantly among the three tertiles of WBD. Correlation between response by relative Curie score and WBD was of borderline significance, with patients receiving a lower WBD showing greater reduction in osteomedullary metastases by Curie score (rs = 0.16, P = 0.049). There were no significant ordered trends among tertiles in any toxicity measures (grade 4 neutropenia, thrombocytopenia < 20,000/μl, and grade > 1 hypothyroidism). CONCLUSIONS: This study showed that (131) I-MIBG activity per kilogram correlates with WBD and suggests that activity per kilogram will predict WBD in most patients. Within the range of activities prescribed, there was no correlation between WBD and either response or toxicity. Future studies should evaluate tumor dosimetry, rather than just WBD, as a tool for predicting response following therapy with (131) I-MIBG.
BACKGROUND: (131) I-metaiodobenzylguanidine ((131) I-MIBG) is a targeted radiopharmaceutical for patients with neuroblastoma. Despite its tumor-specific uptake, the treatment with (131) I-MIBG results in whole-body radiation exposure. Our aim was to correlate whole-body radiation dose (WBD) from (131) I-MIBG with tumor response, toxicities, and other clinical factors. METHODS: This retrospective cohort analysis included 213 patients with high-risk neuroblastoma treated with (131) I-MIBG at UCSF Benioff Children's Hospital between 1996 and 2015. WBD was determined from radiation exposure rate measurements. The relationship between WBD ordered tertiles and variables were analyzed using Cochran-Mantel-Haenszel test of trend, Kruskal-Wallis test, and one-way analysis of variance. Correlation between WBD and continuous variables was analyzed using Pearson correlation and Spearman rank correlation. RESULTS: WBD correlated with (131) I-MIBG administered activity, particularly with (131) I-MIBG per kilogram (P < 0.001). Overall response rate did not differ significantly among the three tertiles of WBD. Correlation between response by relative Curie score and WBD was of borderline significance, with patients receiving a lower WBD showing greater reduction in osteomedullary metastases by Curie score (rs = 0.16, P = 0.049). There were no significant ordered trends among tertiles in any toxicity measures (grade 4 neutropenia, thrombocytopenia < 20,000/μl, and grade > 1 hypothyroidism). CONCLUSIONS: This study showed that (131) I-MIBG activity per kilogram correlates with WBD and suggests that activity per kilogram will predict WBD in most patients. Within the range of activities prescribed, there was no correlation between WBD and either response or toxicity. Future studies should evaluate tumor dosimetry, rather than just WBD, as a tool for predicting response following therapy with (131) I-MIBG.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Tim M Illidge; Mike Bayne; Nicholas S Brown; Samantha Chilton; Mark S Cragg; Martin J Glennie; Yong Du; Valerie Lewington; James Smart; James Thom; Maureen Zivanovic; Peter W M Johnson Journal: Blood Date: 2008-12-12 Impact factor: 22.113
Authors: Shih-ying Huang; Wesley E Bolch; Choonsik Lee; Henry F Van Brocklin; Miguel H Pampaloni; Randall A Hawkins; Aimee Sznewajs; Steven G DuBois; Katherine K Matthay; Youngho Seo Journal: Mol Imaging Biol Date: 2015-04 Impact factor: 3.488
Authors: Michael A Kosmin; Jamshed B Bomanji; Nicholas J Cork; Ananth Shankar; Mark N Gaze Journal: Eur J Nucl Med Mol Imaging Date: 2012-01-04 Impact factor: 9.236
Authors: Pablo Mínguez; Glenn Flux; José Genollá; Sonía Guayambuco; Alejandro Delgado; José Cruz Fombellida; Katarina Sjögreen Gleisner Journal: Med Phys Date: 2015-07 Impact factor: 4.071
Authors: Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca Journal: J Clin Oncol Date: 2009-01-26 Impact factor: 44.544
Authors: Steven G DuBois; Julia Messina; John M Maris; John Huberty; David V Glidden; Janet Veatch; Martin Charron; Randall Hawkins; Katherine K Matthay Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Shakeel Modak; Neeta Pandit-Taskar; Brian H Kushner; Kim Kramer; Peter Smith-Jones; Steven Larson; Nai-Kong V Cheung Journal: Pediatr Blood Cancer Date: 2008-06 Impact factor: 3.167
Authors: S C Clement; K C J M Kraal; B L F van Eck-Smit; C van den Bos; L C M Kremer; G A M Tytgat; H M van Santen Journal: J Clin Endocrinol Metab Date: 2013-12-04 Impact factor: 5.958
Authors: Kelly E Huibregtse; Kieuhoa T Vo; Steven G DuBois; Stephanie Fetzko; John Neuhaus; Vandana Batra; John M Maris; Brian Weiss; Araz Marachelian; Greg A Yanik; Katherine K Matthay Journal: Eur J Cancer Date: 2016-08-27 Impact factor: 9.162